Why the study?
Does selexipag improve outcomes in patients with pulmonary arterial hypertension?
Population
Patients with pulmonary arterial hypertension
Design
Review
Key result
Selexipag is recommended as triple oral combination therapy for PAH with insufficient response to dual therapy, but should not replace parenteral prostacyclin in high-risk patients.
Authors
Loading...
Supports selexipag addition after dual PAH failure; leaves open need for head-to-head trials versus parenteral prostacyclin.
Does selexipag improve outcomes in patients with pulmonary arterial hypertension?
Selexipag is a validated oral prostacyclin receptor agonist that should be considered as part of triple oral combination therapy for PAH when response to dual oral therapy is insufficient.
Genecand et al. (2020) conducted a review in Pulmonary arterial hypertension (PAH). Selexipag was evaluated. Selexipag is recommended as triple oral combination therapy for PAH with insufficient response to dual therapy, but should not replace parenteral prostacyclin in high-risk patients.